Hypertension and benign prostatic hyperplasia (BPH) are common disorders of aging men. As the world population is aging these two diseases are becoming a significant public health problem worldwide. Approximately 30% of men treated for BPH have coexisting hypertension. The α-Adrenergic Blockers: Prazosin, Terazosin and Doxazosin are established agents in the therapy of hypertension, and are als...

This study discussed the effect of whole course comprehensive nursing after operation for benign prostatic hyperplasia (BPH). Eighty-six patients with BPH who were to undergo surgery divided into a control group and based on therapeutic method. 43 in each postoperatively given usual care group. The mental status, prostate symptoms, quality life, complications degree satisfaction compared before...

Prostatic artery embolization (PAE) is a promising new treatment for lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH). It has therefore garnered much interest in the interventional community. This article will review the scientific background for this therapy, describe the current devices available for treatment, and state the position of the Society of Interv...

Background: Cone-beam computed tomography (CBCT) is a new and useful technique for angiographic procedures. Prostatic artery embolization (PAE) has emerged as a promising treatment modality for lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia (BPH). CBCT can be helpful for PAE to determine the correct arteries for embolization, and to show any occlusion of these arteri...

Coronavirus Disease (COVID-19) is accompanied by high comorbidities and a worse prognosis in those with underlying diseases. Older men are more vulnerable to COVID-19 infection Benign Prostatic Hyperplasia (BPH) accounts for large portion of this population, so study presented the clinical paraclinical features 20 patients BPH their outcome. The mean age participants was 76.8 ± 7.9 years. Respi...

Benign prostatic hyperplasia (BPH) is a considerable public health problem prevalent among older men. Despite its eminent prevalence, the etiology of BPH not well understood. Accumulating evidence indicates that modifiable risk factors cardiovascular disease may also increase and potentially contribute to development. This study evaluated ameliorative effect Ceiba pentandra leaf on some lipids ...

AIM To investigate the risk factors for prostatic inflammation extent and infection in patients with benign prostatic hyperplasia (BPH) so as to manage prostatic inflammation more efficiently. METHODS Sixty patients with BPH undergoing TURP between September 2005 and December 2005 in West China Hospital of Sichuan University were studied. Prostate fluid (PF) was collected for the measurement ...

Benign prostatic hyperplasia (BPH) is a common proliferative disorder of unknown etiology. We have previously documented that the insulin-like growth factor (IGF) axis is critical for prostate cell growth and is abnormal in BPH. The type 1 IGF receptor (IGF-1R) is constitutively expressed by most body tissues and plays a significant role in regulating cell proliferation, consistent with the rol...

Our treatment strategies for benign prostatic hyperplasia (BPH) have changed, with new insights into the pathophysiology of the disease, new clinical trials, and surgical advances. We present an update on treatment options and a diagnostic and treatment algorithm for this condition.

Benign prostatic hyperplasia (BPH; Pic. 1) is characterized by increased size of the prostate leading to difficulties with passing the urine. The cells of prostate may increase in numbers (hyperplasia) or in size (hypertrophy) resulting in larger size of prostate. As result, prostatic nodules form in the transition zone of the prostate, which is the area where the prostate is surrounding the ur...